161 related articles for article (PubMed ID: 7753302)
1. [Vitamin D treatment and renal osteodystrophy: indications and modalities].
Fournier A; Morinière P; Yverneau-Hardy P; Westeel PF; Mazouz H; el Esper N; Ghazali A; Boudailliez B
Nephrologie; 1995; 16(2):165-90. PubMed ID: 7753302
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. 1-alpha-Hydroxyvitamin D3 derivatives in the treatment of renal bone diseases: justification and optimal modalities of administration.
Fournier A; Morinière PH; Oprisiu R; Yverneau-Hardy P; Westeel PF; Mazouz H; el Esper N; Ghazali A; Boudailliez B
Nephron; 1995; 71(3):254-83. PubMed ID: 8569975
[TBL] [Abstract][Full Text] [Related]
4. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
5. [Renal osteodystrophy (3); its treatment in dialysis patients].
Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
[TBL] [Abstract][Full Text] [Related]
6. [Renal osteodystrophy (2): its treatment in renal insufficiency before dialysis].
Hottelart C; Bako G; Oprisiu R; Georgita A; Presne C; Sarraj A; Morinière P; el Esper N; Fournier A
Nephrologie; 2000; 21(6):275-82. PubMed ID: 11117106
[TBL] [Abstract][Full Text] [Related]
7. [Hyperparathyroidism secondary to renal insufficiency. Physiopathology, clinicoradiological aspects and treatment].
Ben Hamida F; Ghazali A; Boudzernidj M; Amar M; Morinière P; Westeel P; Fournier A
Ann Endocrinol (Paris); 1994; 55(5):147-58. PubMed ID: 7857079
[TBL] [Abstract][Full Text] [Related]
8. Renal osteodystrophy in dialysis patients: diagnosis and treatment.
Fournier A; Oprisiu R; Hottelart C; Yverneau PH; Ghazali A; Atik A; Hedri H; Said S; Sechet A; Rasolombololona M; Abighanem O; Sarraj A; El Esper N; Moriniere P; Boudailliez B; Westeel PF; Achard JM; Pruna A
Artif Organs; 1998 Jul; 22(7):530-57. PubMed ID: 9684690
[TBL] [Abstract][Full Text] [Related]
9. Use of alkaline calcium salts as phosphate binder in uremic patients.
Fournier A; Morinière P; Ben Hamida F; el Esjer N; Shenovda M; Ghazali A; Bouzernidj M; Achard JM; Westeel PF
Kidney Int Suppl; 1992 Oct; 38():S50-61. PubMed ID: 1405382
[TBL] [Abstract][Full Text] [Related]
10. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.
Mornière P; Maurouard C; Boudailliez B; Westeel PF; Achard JM; Boitte F; el Esper N; Compagnon M; Maurel G; Bouillon R
Nephron; 1992; 60(2):154-63. PubMed ID: 1552999
[TBL] [Abstract][Full Text] [Related]
11. Renal ostodystrophy during the developing stage of maintenance dialysis in Transylvania. Early development of periarticular calcifications and beta 2 microglobulin amyloidosis in spite of a relatively good prevention of secondary hyperparathyroidism.
Oprisiu R; Bolosiu H; Boca I; Theodoru C; Elefterescu R; Brazier M; el Esper I; Leflon P; Ledeme C; Fournier A; Heinze V
Ann Med Interne (Paris); 1998 Mar; 149(2):67-75. PubMed ID: 11490527
[TBL] [Abstract][Full Text] [Related]
12. Management of hyperphosphatemia in patients with renal failure.
Ghazali A; Ben Hamida F; Bouzernidj M; el Esper N; Westeel PF; Fournier A
Curr Opin Nephrol Hypertens; 1993 Jul; 2(4):566-79. PubMed ID: 7859019
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of intermittent oral alphacalcidol, calcium carbonate and low-calcium dialysis (1.25 mmol L-1) on secondary hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis.
Brandi L; Nielsen PK; Bro S; Daugaard H; Olgaard K
J Intern Med; 1998 Aug; 244(2):121-31. PubMed ID: 10095798
[TBL] [Abstract][Full Text] [Related]
15. Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure.
Cozzolino M; Gallieni M; Brancaccio D; Arcidiacono T; Bianchi G; Vezzoli G
J Nephrol; 2006; 19(5):566-77. PubMed ID: 17136683
[TBL] [Abstract][Full Text] [Related]
16. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
Shahapuni I; Mansour J; Harbouche L; Maouad B; Benyahia M; Rahmouni K; Oprisiu R; Bonne JF; Monge M; El Esper N; Presne C; Moriniere P; Choukroun G; Fournier A
Semin Dial; 2005; 18(3):226-38. PubMed ID: 15934970
[TBL] [Abstract][Full Text] [Related]
17. Improvement of severe secondary hyperparathyroidism in dialysis patients by intravenous 1 alpha(OH) vitamin D3, oral CaCO3 and low dialysate calcium.
Moriniere P; el Esper N; Viron B; Judith D; Bourgeon B; Farquet C; Gheerbrant J; Chapuy M; Van Orshoven A; Pamphile R
Kidney Int Suppl; 1993 Jun; 41():S121-4. PubMed ID: 8320904
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of the treatment efficacy of secondary hyperparathyroidism with oral pulse doses of alphacalcidol].
Switalski M; Kuriga M; Wańkowicz Z
Pol Arch Med Wewn; 1997 Oct; 98(10):358-65. PubMed ID: 9557090
[TBL] [Abstract][Full Text] [Related]
19. Renal osteodystrophy and aluminum bone disease in CAPD patients.
Gokal R
Clin Nephrol; 1988; 30 Suppl 1():S64-7. PubMed ID: 3052962
[TBL] [Abstract][Full Text] [Related]
20. High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone.
Bro S; Brandi L; Olgaard K
Nephrol Dial Transplant; 1996 Aug; 11(8):1586-91. PubMed ID: 8856216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]